Morning Briefing
Summaries of health policy coverage from major news organizations
Despite Boards Stocked With D.C. Luminaries, Theranos Still Faces Consequences From Regulators
Politico: Troubled Health Start-Up Theranos Faces Washington Reckoning
Theranos, a $9 billion health care startup, is becoming a poster child for the limited value of having a board stocked with Washington powerbrokers. With insiders ranging from Henry Kissinger to former Senate Majority Leader Bill Frist, Theranos still faces a federal regulatory call Friday that could capsize the firm and threaten an innovative healthcare sector along with it. The Palo Alto, Calif., company, headed by 32-year-old Elizabeth Holmes, has faced growing scientific and financial skepticism over its bold central claim: that it can replace the scary hypodermic needle with a cheap finger prick to test human blood, overturning the lab testing industry in the process. (Tahir, 2/11)
